MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2018 International Congress

    Examining Parkinson’s disease psychosis treatment outcomes in the real world: The insyte observational study

    J. Goldman, D. Fredericks, C. Heywood, A. Ryan, A. Shim (Chicago, IL, USA)

    Objective: The INSYTE Study–seeks to gain a better understanding of the management of PDP. INSYTE will describe the relative safety and effectiveness of various antipsychotic…
  • 2018 International Congress

    Evaluation of Parkinson’s Disease Psychosis Requires Structured Questioning of Patients and Caregivers

    P. Schmidt, F. Cubillos, A. Diaz, P. Wiener, S. Metz, N. Romero, C. Andersson, S. Andes, D. Fredericks, A. Shim (Miami, FL, USA)

    Objective: To determine the relationship between the patient and caregiver experience of the psychotic features of Parkinson's disease psychosis (PDP) reported to call center healthcare…
  • 2018 International Congress

    Patient Experience of Parkinson’s Disease Psychosis Management

    P. Schmidt, F. Cubillos, A. Diaz, P. Wiener, S. Metz, N. Romero, A. Shim, D. Fredericks (Miami, FL, USA)

    Objective: To understand the experience and management of Parkinson’s disease psychosis (PDP). Background: PDP is a troubling non-motor symptom of Parkinson’s disease. Clinical approaches to…
  • 2018 International Congress

    Patterns of Long-Term Custodial Care in Parkinson Disease Psychosis

    J. Wetmore, H. Yan, M. Irfan, A. Shim, Y. Peng, D. Gilbertson, S. Li (Minneapolis, MN, USA)

    Objective: Parkinson Disease (PD) progression is frequently associated with development of psychosis (P), leading to significant morbidity, caregiver distress, and other consequences. Although PDP often…
  • 2018 International Congress

    Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease

    A. Hamadjida, D. Bedard, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A) receptor EMD-281,014 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…
  • 2017 International Congress

    Predictors for psychosis in Huntington’s disease: preliminary analysis of the Enroll-HD database.

    N. Rocha, E. Furr-Stimming, A. Teixeira (Houston, TX, USA)

    Objective: To evaluate predictors for psychosis in HD. Background: Behavioral problems are present across all stages of HD, even preceding the development of the motor…
  • 2017 International Congress

    Parkinson Syndrome associated with inositol-1,4,5-triphosphate receptor antigen type 1 (ITPR1) antibodies

    B. Wimmer, K. Fuchs, U. Bogdahn, A. Heimeroth (Regensburg, Germany)

    Objective: To illustrate an unusual clinical presentation of Parkinson´s disease (PD) that was effectively treated with immune adsorption. Background: Autoimmune mediated movement disorders may be…
  • 2017 International Congress

    Chorea and psychosis as stroke presentation : report and brief review

    F. RADJI (AGEN, France)

    Objective: Describe phenomenology of rare movement disorders in stroke presentation and it pathophysiology Background: Acute movement disorders are a rare presentation of ischaemic stroke. hemichorea…
  • 2017 International Congress

    Late-Onset Wilson’s disease, Dementia, Ekbom syndrome and whitte matter hyperintensities

    F. Germiniani, P. Marques, F. Zorzetto, L. de Oliveira, H. Teive (Curitiba, Brazil)

    Objective: The aim of this study is to describe a patient with late-onset Wilson’s disease, dementia and Ekbom Syndrome. Background: Wilson's disease is an autosomal-recessive disorder…
  • 2017 International Congress

    The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

    I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of mirtazapine, a clinically-available anti-depressant, on psychosis and dyskinesia in Parkinson’s disease (PD). Background: Psychosis and dyskinesia cause significant morbidity…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley